New drug VV261 takes first step: safety check in healthy volunteers
NCT ID NCT07302269
First seen Jan 03, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This early-stage study tests a single dose of an experimental drug called VV261 in 58 healthy adults aged 18 to 45. The goal is to see if the drug is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo, and no one knows who gets what. This study does not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230031, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.